Pridopidine Emerging Drug Insight and Market Forecast - 2032

“Pridopidine Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Pridopidine for Huntington's disease in the 7MM. A detailed picture of the Pridopidine for Huntington's disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Pridopidine for Huntington's disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Pridopidine market forecast, analysis for Huntington's disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Huntington's disease.

Drug Summary

Pridopidine (formerly Huntexil) is Prilenia Therapeutics' lead asset and a first-in-class selective and potent Sigma-1-receptor (S1R) agonist with neuroprotective properties. Activation of the S1R by pridopidine enhances the clearance of toxic proteins, enhances energy production, and reduces cellular stress and inflammation. These mechanisms are crucial for a neuron's function and survival. It is a small molecule that is administered in a small easy-to-swallow capsule twice a day. Pridopidine is under development for the treatment of Huntington's disease (HD) and Amyotrophic Lateral Sclerosis (ALS).

Pridopidine has an extensive safety and tolerability profile and was already evaluated in >1300 people including long-term evaluation for >5 years. Studies in animal models and human cells show that pridopidine prevents neuronal cell death, and strengthens and enhances the connections between neurons. Prilenia is continuing the clinical and preclinical evaluation of pridopidine in various neurodegenerative and neurodevelopmental indications and plans to initiate additional clinical studies in the future.

Currently, Pridopidine is being evaluated in the ongoing Phase III (NCT04556656) global clinical trial PROOF-HD (PRidopidine Outcome on Function in Huntington's disease). As per the company, the successful outcome of PROOF-HD may lead to Pridopidine's approval as a treatment for Huntington's disease. It is estimated to be completed by early 2023.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Pridopidine description, mechanism of action, dosage and administration, research and development activities in Huntington's disease.
• Elaborated details on Pridopidine regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Pridopidine research and development activity in Huntington's disease in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Pridopidine (Deutetrabenazine).
• The report contains forecasted sales of Pridopidine for Huntington's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Huntington's disease.
• The report also features the SWOT analysis with analyst views for Pridopidine in Huntington's disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pridopidine Analytical Perspective

In-depth Pridopidine Market Assessment

This report provides a detailed market assessment of Pridopidine in Huntington's disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

Pridopidine Clinical Assessment

The report provides the clinical trials information of Pridopidine in Huntington's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Huntington's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Pridopidine dominance.
• Other emerging products for Huntington's disease are expected to give tough market competition to Pridopidine and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Pridopidine in Huntington's disease.
• This in-depth analysis of the forecasted sales data from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Pridopidine in Huntington's disease.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Pridopidine?
• What is the clinical trial status of the study related to Pridopidine in Huntington's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Pridopidine development?
• What are the key designations that have been granted to Pridopidine for Huntington's disease?
• What is the forecasted market scenario of Pridopidine for Huntington's disease?
• What are the forecasted sales of Pridopidine in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Huntington's disease and how are they giving competition to Pridopidine for Huntington's disease?
• Which are the late-stage emerging therapies under development for the treatment of Huntington's disease?

This product will be delivered within 2 business days.